08:30 às 09:40 - Sessão 1 - Best of SABCS 2022 - parte 1

08:30 às 08:40 - - GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02